Literature DB >> 19453314

Risk and outcome analysis of renal replacement therapies in patients after cardiac surgery with pre-operatively normal renal function.

D Hauer1, E Kilger, I Kaufmann, S Kreth, A Beiras-Fernandez, J Briegel, G Schelling, M Schmidt, F Weis.   

Abstract

Peri-operative acute renal failure requiring renal replacement therapy is common (5-30%) after cardiac surgery and associated with a mortality of approximately 50%. Pre-operative renal impairment seems to be the most important risk factor for frank postoperative renal failure. To help evaluate the risk factors, we conducted a prospective observational trial of 1574 consecutive patients with normal pre-operative renal function (creatinine < 110 micromol.l(-1)). Renal failure was defined as the need for renal replacement therapy. After univariate analysis of previously described risk factors, those who differed significantly between patients with or without renal failure were enrolled into a multivariate classification and regression tree (CART) statistical model that identifies the most 'predictive' risk factors and creates a ranked list of these. In patients with pre-operatively normal renal function, a serum level of lactate > 1.1 mmol.l(-1) in the first 24 h after the operation was the strongest predictor for the development of renal failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453314     DOI: 10.1111/j.1365-2044.2009.05889.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  3 in total

1.  The impact of major perioperative renal insult on long-term renal function and survival after cardiac surgery.

Authors:  Vivek Srivastava; Celma D'Silva; Augustine Tang; Franco Sogliani; Dumbor L Ngaage
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-04-02

2.  [Daptomycin for the treatment of gram-positive infections after cardiac surgery].

Authors:  B Luchting; F Weis; J Heyn; A Beiras-Fernandez
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-11-14       Impact factor: 0.840

3.  Daptomycin for the treatment of major gram-positive infections after cardiac surgery.

Authors:  A Kornberger; B Luchting; F Kur; M Weis; F Weis; U A Stock; A Beiras-Fernandez
Journal:  J Cardiothorac Surg       Date:  2016-08-04       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.